Shots:

• miRecule to receive ~$30M up front incl. near-term milestones & is also eligible to receive ~$400M in development, regulatory, and commercial milestones to advance FSHD drug candidate along with royalties on global net sales of the approved product. Both companies collaborated on research activities through lead candidate selection 
• Sanofi gets an exclusive license to IP rights globally for FSHD therapy (developed and commercialized by Sanofi) & will be responsible for IND enabling studies along with development and commercialization activities globally
• The collaboration combines miRecule’s anti-DUX4 RNA therapy with Sanofi’s NANOBODY technology for Ab-RNA conjugate (ARC) to treat FSHD by using NAVIgGator conjugation and formulation chemistry

Ref: Businesswire | Image: Estrella